DiaMedica Therapeutics Inc (DMAC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DiaMedica Therapeutics Inc (DMAC) has a cash flow conversion efficiency ratio of -0.192x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.08 Million) by net assets ($47.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DMAC market cap for the company's overall valuation and market capitalisation.
DiaMedica Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how DiaMedica Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
DiaMedica Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DiaMedica Therapeutics Inc ranked by their cash flow conversion efficiency. See DMAC operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenwu Energy Saving Co Ltd
SHE:000820
|
-0.017x |
|
Lifezone Metals Limited
NYSE:LZM
|
-0.117x |
|
Jupiter Mines Ltd
AU:JMS
|
0.023x |
|
Chongqing YuXin Pingrui Electronic Co. Ltd.
SHE:301107
|
0.011x |
|
Jiangsu Xinri E-Vehicle Co Ltd
SHG:603787
|
0.161x |
|
Intellian Technologies Inc
KQ:189300
|
-0.015x |
|
Century Therapeutics Inc
NASDAQ:IPSC
|
-0.085x |
|
Rejlers AB (publ)
ST:REJL-B
|
0.029x |
Annual Cash Flow Conversion Efficiency for DiaMedica Therapeutics Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of DiaMedica Therapeutics Inc from 2004 to 2025. View DiaMedica Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $56.11 Million | $-29.06 Million | -0.518x | +4.47% |
| 2024-12-31 | $40.72 Million | $-22.08 Million | -0.542x | -47.81% |
| 2023-12-31 | $51.06 Million | $-18.73 Million | -0.367x | -1.42% |
| 2022-12-31 | $31.83 Million | $-11.51 Million | -0.362x | -29.96% |
| 2021-12-31 | $44.02 Million | $-12.25 Million | -0.278x | +21.18% |
| 2020-12-31 | $26.01 Million | $-9.19 Million | -0.353x | +70.45% |
| 2019-12-31 | $7.62 Million | $-9.10 Million | -1.195x | -257.17% |
| 2018-12-31 | $17.02 Million | $-5.70 Million | -0.335x | +93.15% |
| 2017-12-31 | $799.00K | $-3.90 Million | -4.881x | -101.17% |
| 2016-12-31 | $1.25 Million | $-3.02 Million | -2.426x | -318.40% |
| 2015-12-31 | $-1.23 Million | $-1.37 Million | 1.111x | -54.77% |
| 2014-12-31 | $-1.53 Million | $-3.76 Million | 2.456x | +161.68% |
| 2013-12-31 | $1.38 Million | $-5.50 Million | -3.983x | -64.48% |
| 2012-12-31 | $2.26 Million | $-5.48 Million | -2.421x | -320.16% |
| 2011-12-31 | $5.96 Million | $-3.44 Million | -0.576x | -106.67% |
| 2010-12-31 | $8.52 Million | $-2.38 Million | -0.279x | +86.39% |
| 2009-12-31 | $1.05 Million | $-2.15 Million | -2.049x | -288.44% |
| 2008-12-31 | $2.78 Million | $-1.47 Million | -0.528x | -76.73% |
| 2007-12-31 | $4.06 Million | $-1.21 Million | -0.299x | +75.65% |
| 2006-12-31 | $653.60K | $-801.16K | -1.226x | +25.36% |
| 2005-12-31 | $506.11K | $-831.17K | -1.642x | -1852.50% |
| 2004-12-31 | $-1.06 Million | $-99.35K | 0.094x | -- |
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal… Read more